ArticleFEBS open bio2026
A general model for analysis of linear and hyperbolic enzyme inhibition mechanisms.
Article in FEBS open bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The mechanisms of reversible inhibitors with a single binding site on enzymes are usually divided into two basic groups: linear and hyperbolic (or partial). Each of these two groups is subdivided into three types: competitive, non-competitive and mixed. These six mechanisms are often considered separate identities. Here, prompted by the characterization of the inhibition of the wild-type and mutant β-glucosidase Sfβgly by imidazole and 2-amino-2-(hydroxymethyl)-1,3-propanediol (i.e. Tris), we developed a unifying enzyme kinetic model that integrates these six basic inhibition mechanisms into one. From this model, we deduced a general enzyme kinetic equation that, through modulation of simple parameters (i.e. the relative inhibitor affinity for two binding sites and the reactivity of the enzyme-substrate-inhibitor complex) is converted into the particular kinetic equation of each of those six inhibition mechanisms. In short, we conclude that the six fundamental inhibition mechanisms, linear and hyperbolic, are not separate behaviors but facets of the same general kinetic model presented here.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.